Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade.

Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one-off events, not demand weakness.

Gross margin was impacted by temporary costs but is expected to improve to 50%+ as internal manufacturing scales and opex reductions take effect.

Cash runway now extends well into 2028, and pipeline expansion offers upside optionality, though Amtagvi in melanoma remains the core story.

Iovance Biotherapeutics Overview My last analysis on Iovance Biotherapeutics (IOVA) followed its Q4 earnings report.

This is a company that markets Amtagvi (lifileucel), which is a tumor-infiltrating lymphocyte, or TIL, therapy that is used primarily in patients.